| Symbol | HOPHF |
|---|---|
| Name | HEMOGENYX PHARMACEUTICALS PLC. |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | EC3V 0HR United Kingdom ENG 60 Gracechurch Street, 6th Floor |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://hemogenyx.com/ |
| Incorporation | GB |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: LSE - London Stock Exchange |
| CIK | — |
| Description | Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The companys lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Additional info from OTC: |
No news found.